James Harrow, PhD
Addiction Medicine · Montgomery, ALNPI 1104992411
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 24.2% of the total. 2025 is the largest year on record at $530, more than ten times the $48 reported in 2019.
Across 109 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$478
- Johnson & Johnson$307
- Pfizer$151
- Corium, LLC$109
- Novo Nordisk$98
- Indivior Inc.$95
- plus $740 from 24 others
What the payments were for
- Food & beverage$1,979100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 25 | $478 |
| Johnson & Johnson | 19 | $307 |
| Pfizer | 9 | $151 |
| Corium, LLC | 6 | $109 |
| Novo Nordisk | 5 | $98 |
| Indivior Inc. | 3 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Dexcom, Inc. | 5 | $84 |
| GSK | 5 | $76 |
| Amarin Pharma, Inc. | 3 | $52 |
| Tris Pharma Inc | 2 | $39 |
| AstraZeneca(2 entities) | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Amgen | 2 | $29 |
| Philips North America LLC | 1 | $28 |
| Boehringer Ingelheim | 1 | $26 |
| Inogen, Inc. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $21 |
| Abbott | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
| Ossur Americas, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| Otsuka America Pharmaceutical, Inc. | 1 | $11 |
| Intra-sana Laboratories | 1 | $11 |
How this compares
Too few addiction medicine providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 258 | $56,643 |
| Clonazepam | 22 | $582 |
| Naltrexone Hcl | 11 | $559 |
| Gabapentin | 28 | $517 |
| Doxepin Hcl | 22 | $451 |
| Quetiapine Fumarate | 27 | $219 |
| Amitriptyline Hcl | 22 | $218 |
| Baclofen | 11 | $162 |
| Diazepam | 42 | $85 |
| Lorazepam | 16 | $61 |
| Buspirone Hcl | 12 | $59 |
| Trazodone Hcl | 16 | $36 |
| Fluoxetine Hcl | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Montgomery
- Michael WilkersonWarrior$40K
- Stephen TaylorBirmingham$6K
- William LemonsHoover$910
- Ann StillAthens$822
- Wilbur WellsBirmingham$395
- Donald WilliamsJasper$374
- Dylan CaggianoMobile$292
- Peter LaneBirmingham$202
- Nancy WhiteHuntsville$74
- Thomas MoodyHomewood$69
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.